Clinical Trial

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

Staff January 11, 2023

Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023...

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

Staff January 11, 2023

Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market...

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

Staff January 11, 2023

Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023NEW YORK, Jan. 11, 2023 (GLOBE...

BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

Staff January 11, 2023

Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at...

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Staff January 11, 2023

VANCOUVER, British Columbia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT:...

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Staff January 11, 2023

HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for...

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

Staff January 11, 2023

LA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...

Adaptive Research Expands Clinical Programs and Appoints Perminder Bhatia, M.D. as Head of Neurology

Staff January 10, 2023

SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization with a unique purpose...

VIVUS Announces Key Management Updates to Support Global Expansion Strategy

Staff January 10, 2023

CAMPBELL, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- VIVUS LLC today announced the promotion of Santosh T. Varghese, MD, to...

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Staff January 10, 2023

CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life...

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

Staff January 10, 2023

Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhoreTM platform’s functionality with mRNA, and:Peptide-based...

Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million

Staff January 10, 2023

Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 (GLOBE...

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Staff January 10, 2023

Topline data expected in the first half of 2023SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:...

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Staff January 10, 2023

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE:...

Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan

Staff January 10, 2023

Lake Street Capital Markets LLC engaged to act as an advisor to the CompanyBoard of Directors approved restructuring program with...

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

Staff January 10, 2023

MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...

BrainsWay Resolves Neuronetics Litigation

Staff January 10, 2023

BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

Staff January 10, 2023

Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is...

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Staff January 10, 2023

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in...

Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine

Staff January 10, 2023

Eflornithine method for use patent from Michigan State University/Corewell Health® relates to treating patients with rare Bachmann-Bupp SyndromePALO ALTO, Calif.,...

Clinical Trial

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

Adaptive Research Expands Clinical Programs and Appoints Perminder Bhatia, M.D. as Head of Neurology

VIVUS Announces Key Management Updates to Support Global Expansion Strategy

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

BrainsWay Resolves Neuronetics Litigation

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

LULUTOX Detox Tea in Consumer Coverage as Website Update Introduces More Transparency in Herbal Digestive Supplement Information

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

Profound Medical Corp. Announces Upsize of Private Placement

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

You may have missed